Related Experiment Video
Updated: May 9, 2025

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
Published on: May 10, 2021
Endocrine Mucin Producing Sweat Gland Carcinoma Treated With Mohs Micrographic Surgery: A Systematic Review
Background:
Endocrine Mucin Producing Sweat Gland Carcinoma (EMPSGC) is a low-grade, cutaneous adnexal neoplasm. It is believed to have a potential for local recurrence as well as distant metastases in rare cases.
Objective:
This study's purpose is to compare recurrence rates and outcomes between EMPSGC undergoing Mohs micrographic surgery (MMS) and traditional surgical excision.
Methods:
A comprehensive review of the literature was performed using the following keywords: "Endocrine Mucin Producing Sweat Gland Carcinoma" and/or "EMPSGC" and/or "Mohs Micrographic Surgery" and/or "MMS" and/or "wide local excision" and/or "excision."
Results:
There were 17 articles and 27 patients identified between the two databases. The procedures included 17 MMS and 13 surgical excisions. Patients treated with MMS typically had a lower incidence of recurrence (11.8%). In contrast, patients treated with surgical excision had a higher recurrence rate (46.2%).
Limitations:
This study is limited by the small number of cases identified in our literature search and the variability in follow-up duration among the cases.
Conclusions:
MMS demonstrated less recurrence of EMPSGC compared with surgical excision. Further research with large sample sizes would be beneficial in optimizing the surgical treatment approach for EMPSGC.
Citation:
Wittmer A, Arora N, Shalabi MMK, et al. Endocrine mucin producing sweat gland carcinoma treated with Mohs micrographic surgery: a systematic review. J Drugs Dermatol. 2025;24(5):498-501. doi:10.36849/JDD.8713.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019